A Limited Access Phase II Trial Of Capecitabine In Advanced, Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix
- Determine the activity of capecitabine in patients with advanced, persistent, or
recurrent squamous cell carcinoma of the cervix.
- Determine the toxicity profile of this drug in this patient population.
OUTLINE: This is a multicenter study.
Patients receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in
the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
PROJECTED ACCRUAL: A total of 28-62 patients will be accrued for this study within 9-20
Primary Purpose: Treatment
Agustin Garcia, MD
USC/Norris Comprehensive Cancer Center
United States: Federal Government
|Chao Family Comprehensive Cancer Center||Orange, California 92868|
|Indiana University Cancer Center||Indianapolis, Indiana 46202-5265|
|University of Mississippi Medical Center||Jackson, Mississippi 39216-4505|
|Comprehensive Cancer Center at Wake Forest University||Winston-Salem, North Carolina 27157-1082|
|Brookview Research, Inc.||Nashville, Tennessee 37203|
|University of Texas Medical Branch||Galveston, Texas 77555-1329|
|Keesler Medical Center - Keesler AFB||Keesler AFB, Mississippi 39534-2576|
|Holden Comprehensive Cancer Center||Iowa City, Iowa 52242-1009|
|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support||Bethesda, Maryland 20892-1182|